00047-la Tdr
This document was uploaded by user and they confirmed that they have the permission to share it. If you are author or own the copyright of this book, please report to us by using this DMCA report form. Report DMCA
Overview
Download & View 00047-la Tdr as PDF for free.
More details
- Words: 1,333
- Pages: 4
FEBRUARY 2004
Highlights From DAWN: Los Angeles, 2002 Top 5 drugs in drug abuserelated ED visits in Los Angeles, 2002 12,000
10,049 9,364 9,000 Number of visits
This special report presents findings based on data submitted by 29 hospitals in the Los Angeles metropolitan area for 2002. ❋ Of the 2.7 million visits to Los Angeles area emergency departments (EDs) in 2002, about one percent (24,592) were related to drug abuse. ❋ During 2002, the most common drugs involved in ED visits in the Los Angeles area were alcohol in combination with other drugs, cocaine, marijuana, heroin, benzodiazepines, and narcotic analgesics (pain relievers). ❋ In 2002, narcotic pain relievers and benzodiazepines were each as frequent as heroin in drug abuserelated ED visits in Los Angeles.
6,000
5,593
3,000
2,525
2,428
Heroin
Benzo� diazepines
0 Alcoholin� Cocaine combination
Marijuana
DAWN: The Warning Network Local information is essential to Seattle support local action, and drugs, drug use, and drugrelated morbidity can Detroit Minneapolis differ dramatically across communities. Buffalo DAWN focuses on metropolitan areas Chicago Baltimore to reveal emerging drug problems Denver San Francisco Washington St. Louis before they become widespread. DAWN detects new drugs, new drug Los Angeles combinations, new health consequences Atlanta Phoenix Dallas of drug use, and changing patterns involving San� old drugs. Facilities participating in DAWN Diego can use this information to train staff and New� improve patient care. Communities can use this Orleans Miami information to plan, target resources, and act more effectively. Today, hospitals in Los Angeles and 20 other metropolitan areas serve their communities by participating in DAWN. Expansion to other areas is underway.
Boston New York Newark Philadelphia
DAWN serves a diverse audience. In addition to participating facilities, users include researchers and policy analysts; pharmaceutical firms; State and local substance abuse agencies; community coalitions; and Federal agencies, including the White House Office of National Drug Control Policy, the Food and Drug Administration, and the National Institute on Drug Abuse. For more information, go to http://DAWNinfo.samhsa.gov/.
2
T H E DA W N R E P O RT •
F E B R UA RY 2 0 0 4
Trends in Top 4 Drugs, 19952002 Cocaine
❋
Cocainerelated ED visits in Los Angeles increased
77 percent between 1995 and 2002 (from 61 to
108 visits per 100,000 population). Over the same
period, the national rate rose 33 percent (from 58
to 78 visits per 100,000 population).
Almost threequarters (72%) of cocainerelated ED visits in Los Angeles also involved other drugs. About onequarter (27%) of cocainerelated ED visits were attributed to "crack."
150
Los Angeles Rate per 100,000 population
❋
100
U.S. 50
0
1995
1996
1997
1998
1999
2000
2001
2002
Marijuana
❋
From 1995 to 2002, marijuanarelated ED visits
in Los Angeles more than tripled (from 21 to 64
visits per 100,000 population). Over the same
period, the national rate increased 139 percent
(from 19 to 47 per 100,000 population).
Marijuana was reported in about onequarter (23%) of all drug abuserelated ED visits in Los Angeles; most of these visits (85%) involved marijuana with other drugs.
150
Rate per 100,000 population
❋
100
Los Angeles 50
U.S. 0
1995
1996
1997
1998
1999
2000
2001
2002
Heroin
❋
In 2002, the rate of heroinrelated ED visits in
Los Angeles (29 per 100,000 population) was
similar to the national rate (36 per 100,000)
when sampling error is taken into account.
Heroinrelated ED visits in Los Angeles
decreased 21 percent between 2000 and 2002,
while the national rate was stable.
About half (52%) of heroinrelated ED visits in Los Angeles also involved other drugs.
75
Rate per 100,000 population
❋
50
U.S. 25
0
Los Angeles
1995
1996
1997
1998
1999
2000
2001
2002
Benzodiazepines
❋
In Los Angeles, mentions of benzodiazepines in drug abuserelated ED visits have been relatively stable from 1995 to 2002. Over the same period, the national rate rose 25 percent (from 33 to 41 mentions per 100,000). Alprazolam, clonazepam, lorazepam, and diazepam were the most frequently named benzodiazepines in drug abuserelated ED visits in Los Angeles in 2002.
75
Rate per 100,000 population
❋
50
U.S. Los Angeles
25
0
1995
1996
1997
1998
1999
2000
2001
2002
T H E DA W N R E P O RT •
F E B R UA RY 2 0 0 4
3
??? Comparisons Across 21 Metropolitan Areas
The following figures show Los Angeles in relation to the Nation and 20 other metropolitan areas represented in DAWN for selected drugs in 2002. Comparisons across areas are possible because the number of visits for each drug is represented in terms of a rate per 100,000 population. Not all differences0 in rates are statistically significant.
Cocaine visits�
Marijuana visits�
Rate per 100,000 population, 2002
Rate per 100,000 population, 2002
78
Total U.S.
47
Total U.S.
Chicago
275
Philadelphia
Philadelphia
274
Detroit
257
Baltimore
182
88
Baltimore
171
Chicago
New York
166� � 164� � 156
New Orleans
Boston
96
Atlanta
Buffalo Seattle
111
Miami
186
Detroit
119
Boston
239
Atlanta Newark
124
St. Louis
240
Miami
150 146
78 72� � 65� � 64
Seattle Los Angeles
St. Louis
153
Buffalo
56
San Francisco
150
Washington, DC
55
145
New Orleans 82� � 71
Denver Washington, DC
Minneapolis
47� � 46 46 39
San Francisco
46
Dallas
47
Phoenix
55
38
Denver
32
San Diego 0
New York San Diego
59
Phoenix Minneapolis
54
Newark
108
Los Angeles
27
Dallas
0
300
0
160
Heroin visits�
Benzodiazepines visits�
Rate per 100,000 population, 2002
Rate per 100,000 population, 2002
36
Total U.S.
41
Total U.S. 220
Chicago
214
Newark
203
Baltimore 171
San Francisco
95
Philadelphia 82
New Orleans
78
St. Louis
128
Seattle
69
Detroit
123
New York
102
Boston
60
Baltimore
Boston
111
Newark
Philadelphia
109
Phoenix
53
Seattle
50� � 49� � 47
93� � 93� � 85
Buffalo Detroit Miami
Miami Chicago
New Orleans
53
San Diego
St. Louis
51
San Francisco
43
Denver
38
Washington, DC
35
Atlanta
34
29
Dallas
San Diego
28
Los Angeles
23
0
26 22
New York
10
Dallas
26
Denver
16
Minneapolis
30 28
Minneapolis
20
Atlanta
45 42
Buffalo
Los Angeles Phoenix
57
21
Washington, DC 225
0
130
4
T H E DA W N R E P O RT •
F E B R UA RY 2 0 0 4
??? About DAWN
The Drug Abuse Warning Network (DAWN) is a national surveillance system that monitors drugrelated morbidity and mortality. Section 505 of the Public Health Service Act assigns this responsibility to the Substance Abuse and Mental Health Services Administration (SAMHSA), an agency of the U.S. Department of Health and Human Services. The Act requires SAMHSA to report annually on drugrelated visits to hospital emergency departments and on drugrelated deaths reviewed by medical examiners and coroners. SAMHSA has a contract with Westat, a private research firm based in Rockville, MD, to operate the DAWN system. DAWN collects data from a scientific sample of hospital emergency departments and a set of medical examiners and coroners from across the U.S., with concentrations in selected metropolitan areas. Each participating facility has a DAWN Reporter who is specially trained to identify DAWN cases by retrospectively reviewing emergency department medical records or death investigation case files. No patient, family member, or physician is ever interviewed. No direct identifiers for individual patients or decedents are collected. Beginning in 2003, DAWN cases include any emergency department visit or death that was related to drug use. Reportable cases include drug abuse, misuse, overmedication, accidental and malicious poisonings, and adverse drug reactions. For each case, the DAWN Reporter submits a case report detailing the specific drugs involved, and characteristics of the patient or decedent and event (visit or death). Patient and decedent characteristics include demographics (age, gender, race/ethnicity) and ZIP code. Other data items include date/time, chief complaint, diagnoses, and disposition for each emergency department visit; and date, cause, manner, and place of death for each decedent.
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
Highlights From DAWN: Los Angeles, 2002 Top 5 drugs in drug abuserelated ED visits in Los Angeles, 2002 12,000
10,049 9,364 9,000 Number of visits
This special report presents findings based on data submitted by 29 hospitals in the Los Angeles metropolitan area for 2002. ❋ Of the 2.7 million visits to Los Angeles area emergency departments (EDs) in 2002, about one percent (24,592) were related to drug abuse. ❋ During 2002, the most common drugs involved in ED visits in the Los Angeles area were alcohol in combination with other drugs, cocaine, marijuana, heroin, benzodiazepines, and narcotic analgesics (pain relievers). ❋ In 2002, narcotic pain relievers and benzodiazepines were each as frequent as heroin in drug abuserelated ED visits in Los Angeles.
6,000
5,593
3,000
2,525
2,428
Heroin
Benzo� diazepines
0 Alcoholin� Cocaine combination
Marijuana
DAWN: The Warning Network Local information is essential to Seattle support local action, and drugs, drug use, and drugrelated morbidity can Detroit Minneapolis differ dramatically across communities. Buffalo DAWN focuses on metropolitan areas Chicago Baltimore to reveal emerging drug problems Denver San Francisco Washington St. Louis before they become widespread. DAWN detects new drugs, new drug Los Angeles combinations, new health consequences Atlanta Phoenix Dallas of drug use, and changing patterns involving San� old drugs. Facilities participating in DAWN Diego can use this information to train staff and New� improve patient care. Communities can use this Orleans Miami information to plan, target resources, and act more effectively. Today, hospitals in Los Angeles and 20 other metropolitan areas serve their communities by participating in DAWN. Expansion to other areas is underway.
Boston New York Newark Philadelphia
DAWN serves a diverse audience. In addition to participating facilities, users include researchers and policy analysts; pharmaceutical firms; State and local substance abuse agencies; community coalitions; and Federal agencies, including the White House Office of National Drug Control Policy, the Food and Drug Administration, and the National Institute on Drug Abuse. For more information, go to http://DAWNinfo.samhsa.gov/.
2
T H E DA W N R E P O RT •
F E B R UA RY 2 0 0 4
Trends in Top 4 Drugs, 19952002 Cocaine
❋
Cocainerelated ED visits in Los Angeles increased
77 percent between 1995 and 2002 (from 61 to
108 visits per 100,000 population). Over the same
period, the national rate rose 33 percent (from 58
to 78 visits per 100,000 population).
Almost threequarters (72%) of cocainerelated ED visits in Los Angeles also involved other drugs. About onequarter (27%) of cocainerelated ED visits were attributed to "crack."
150
Los Angeles Rate per 100,000 population
❋
100
U.S. 50
0
1995
1996
1997
1998
1999
2000
2001
2002
Marijuana
❋
From 1995 to 2002, marijuanarelated ED visits
in Los Angeles more than tripled (from 21 to 64
visits per 100,000 population). Over the same
period, the national rate increased 139 percent
(from 19 to 47 per 100,000 population).
Marijuana was reported in about onequarter (23%) of all drug abuserelated ED visits in Los Angeles; most of these visits (85%) involved marijuana with other drugs.
150
Rate per 100,000 population
❋
100
Los Angeles 50
U.S. 0
1995
1996
1997
1998
1999
2000
2001
2002
Heroin
❋
In 2002, the rate of heroinrelated ED visits in
Los Angeles (29 per 100,000 population) was
similar to the national rate (36 per 100,000)
when sampling error is taken into account.
Heroinrelated ED visits in Los Angeles
decreased 21 percent between 2000 and 2002,
while the national rate was stable.
About half (52%) of heroinrelated ED visits in Los Angeles also involved other drugs.
75
Rate per 100,000 population
❋
50
U.S. 25
0
Los Angeles
1995
1996
1997
1998
1999
2000
2001
2002
Benzodiazepines
❋
In Los Angeles, mentions of benzodiazepines in drug abuserelated ED visits have been relatively stable from 1995 to 2002. Over the same period, the national rate rose 25 percent (from 33 to 41 mentions per 100,000). Alprazolam, clonazepam, lorazepam, and diazepam were the most frequently named benzodiazepines in drug abuserelated ED visits in Los Angeles in 2002.
75
Rate per 100,000 population
❋
50
U.S. Los Angeles
25
0
1995
1996
1997
1998
1999
2000
2001
2002
T H E DA W N R E P O RT •
F E B R UA RY 2 0 0 4
3
??? Comparisons Across 21 Metropolitan Areas
The following figures show Los Angeles in relation to the Nation and 20 other metropolitan areas represented in DAWN for selected drugs in 2002. Comparisons across areas are possible because the number of visits for each drug is represented in terms of a rate per 100,000 population. Not all differences0 in rates are statistically significant.
Cocaine visits�
Marijuana visits�
Rate per 100,000 population, 2002
Rate per 100,000 population, 2002
78
Total U.S.
47
Total U.S.
Chicago
275
Philadelphia
Philadelphia
274
Detroit
257
Baltimore
182
88
Baltimore
171
Chicago
New York
166� � 164� � 156
New Orleans
Boston
96
Atlanta
Buffalo Seattle
111
Miami
186
Detroit
119
Boston
239
Atlanta Newark
124
St. Louis
240
Miami
150 146
78 72� � 65� � 64
Seattle Los Angeles
St. Louis
153
Buffalo
56
San Francisco
150
Washington, DC
55
145
New Orleans 82� � 71
Denver Washington, DC
Minneapolis
47� � 46 46 39
San Francisco
46
Dallas
47
Phoenix
55
38
Denver
32
San Diego 0
New York San Diego
59
Phoenix Minneapolis
54
Newark
108
Los Angeles
27
Dallas
0
300
0
160
Heroin visits�
Benzodiazepines visits�
Rate per 100,000 population, 2002
Rate per 100,000 population, 2002
36
Total U.S.
41
Total U.S. 220
Chicago
214
Newark
203
Baltimore 171
San Francisco
95
Philadelphia 82
New Orleans
78
St. Louis
128
Seattle
69
Detroit
123
New York
102
Boston
60
Baltimore
Boston
111
Newark
Philadelphia
109
Phoenix
53
Seattle
50� � 49� � 47
93� � 93� � 85
Buffalo Detroit Miami
Miami Chicago
New Orleans
53
San Diego
St. Louis
51
San Francisco
43
Denver
38
Washington, DC
35
Atlanta
34
29
Dallas
San Diego
28
Los Angeles
23
0
26 22
New York
10
Dallas
26
Denver
16
Minneapolis
30 28
Minneapolis
20
Atlanta
45 42
Buffalo
Los Angeles Phoenix
57
21
Washington, DC 225
0
130
4
T H E DA W N R E P O RT •
F E B R UA RY 2 0 0 4
??? About DAWN
The Drug Abuse Warning Network (DAWN) is a national surveillance system that monitors drugrelated morbidity and mortality. Section 505 of the Public Health Service Act assigns this responsibility to the Substance Abuse and Mental Health Services Administration (SAMHSA), an agency of the U.S. Department of Health and Human Services. The Act requires SAMHSA to report annually on drugrelated visits to hospital emergency departments and on drugrelated deaths reviewed by medical examiners and coroners. SAMHSA has a contract with Westat, a private research firm based in Rockville, MD, to operate the DAWN system. DAWN collects data from a scientific sample of hospital emergency departments and a set of medical examiners and coroners from across the U.S., with concentrations in selected metropolitan areas. Each participating facility has a DAWN Reporter who is specially trained to identify DAWN cases by retrospectively reviewing emergency department medical records or death investigation case files. No patient, family member, or physician is ever interviewed. No direct identifiers for individual patients or decedents are collected. Beginning in 2003, DAWN cases include any emergency department visit or death that was related to drug use. Reportable cases include drug abuse, misuse, overmedication, accidental and malicious poisonings, and adverse drug reactions. For each case, the DAWN Reporter submits a case report detailing the specific drugs involved, and characteristics of the patient or decedent and event (visit or death). Patient and decedent characteristics include demographics (age, gender, race/ethnicity) and ZIP code. Other data items include date/time, chief complaint, diagnoses, and disposition for each emergency department visit; and date, cause, manner, and place of death for each decedent.
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES
Related Documents
Tdr
April 2020 18
Tdr
May 2020 27
Tdr Auxiliar.pdf
May 2020 14
Tdr Virus.docx
May 2020 11
Tdr Bicapa.docx
June 2020 11